Pharmacogenetics of clopidogrel: Comparison between a standard and a rapid genetic testing

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 6, 2012, Pages 500-503

  Saracini, Claudia ^a   Vestrini, Anna ^a   Galora, Silvia ^a   Armillis, Alessandra ^a   Abbate, Rosanna ^a   Giusti, Betti ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; TAQMAN; UNCLASSIFIED DRUG; VERIGENE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; GENOTYPING TECHNIQUE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; THROMBOCYTE FUNCTION; TURNAROUND TIME;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; GENETIC TESTING; GENOTYPE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE; TIME FACTORS;

EID: 84862992613     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0259     Document Type: Article

References (20)

1. Bhatt DL, Bertrand ME, Berger PB, et al. (2002) Meta-analysis of randomized and registry comparison of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39:9-14. (Pubitemid 34059855)
2. Bonello L, Tantry US, Marcucci R, et al. (2010) Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol56:919-933.
3. Brandt JT, Close SL, Iturria SJ, et al. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436. (Pubitemid 350154353)
4. de Morais SM, Wilkinson GR, Blaisdell J, et al. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
5. Giusti B, Gori AM, Marcucci R, et al. (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogen Genomics 17: 1057-1064. (Pubitemid 351339490)
6. Giusti B, Gori AM, Marcucci R, et al. (2010a) Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics Personalized Med 3:33-50.
7. Giusti B, Gori AM, Marcucci R, et al. (2010b) Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol 6:393-407.
8. Hulot JS, Bura A, Villard E, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247. (Pubitemid 44497506)
9. Hulot JS, Collet JP, Silvain J, et al. (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol56:134-143.
10. McFadden EP, Stabile E, Regar E, et al. (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519-1521. (Pubitemid 39410418)
11. Mega JL, Simon T, Collet JP, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830.
12. Mehta SR, Yusuf S, Peters RJ, et al. (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527-533. (Pubitemid 32772726)
13. Pereillo JM, Maftouh M, Andrieu A, et al. (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295. (Pubitemid 35265838)
14. Savi P, Zachayus JL, Delesque-Touchard N, et al. (2006) The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 103:11069-11074. (Pubitemid 44148419)
15. Sibbing D, Koch W, Gebhard D, et al. (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518.
16. Sofi F, Giusti B, Marcucci R, et al. (2011) Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11:199-206.
17. Sofi F, Marcucci R, Gori AM, et al. (2010) Clopidogrel nonresponsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost 103:841-848.
18. Steinhubl SR, Berger PB, Mann JT III, et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420. (Pubitemid 35340537)
19. Trenk D, Hochholzer W, Fromm MF, et al. (2008) Cytochrome P450 2C19 681G> A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-1934. (Pubitemid 351636443)
20. Xie HG, Kim RB, Wood AJ, et al. (2001) Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 41:815-850. (Pubitemid 32385908)